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Retroperitoneal tumors can pose a diagnostic and therapeutic challenge to gynecologists
because of their rarity, late presentation, and complex anatomical location in the retroperi-
toneum. This article reviews the diagnosis and management of retroperitoneal tumors in
the pelvis, and highlights the potential pitfalls that may be faced by gynecologists.
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INTRODUCTION
Retroperitoneal tumors in the pelvis represent a problematic entity
of surgical pathology, because of its rarity, difficulty of diagno-
sis, high recurrence rate after surgical excision, and unpredictable
response to adjuvant therapy. Due to the inaccessible anatomical
position and late clinical presentation, the diagnosis of retroperi-
toneal tumors is often made with delay, in the advanced stages of
local or systemic spread. As a result, many of these cases do not
benefit from complete surgical removal, and this renders a real
diagnostic and therapeutic predicament in gynecology.
In this paper, we review the diagnosis and management of
retroperitoneal tumors in the pelvis, and highlight the poten-
tial diagnostic and therapeutic challenges that may be faced by
gynecologists. A literature search was conducted using PubMed.
The keywords used for the search included “pelvic retroperitoneal
tumors,”“retroperitoneal neoplasms,”“diagnosis,”“investigations,”
and “management.” Relevant papers of all article types published
in English in the last 10 years were reviewed and selected for
inclusion based on relevance to our article.
ANATOMY OF THE RETROPERITONEUM
The retroperitoneum represents a complex potential space con-
taining multiple vital structures limited anteriorly by the peri-
toneum, posteriorly by the posterior abdominal wall, superiorly
by the 12th rib and vertebra, inferiorly by the base of the sacrum
and iliac crest, and laterally by the borders of the quadratus lumb-
ora muscles. This space contains the connective tissue, kidneys,
ureters, adrenal glands, aorta and its branches, inferior vena cava
and its tributaries, and lymph nodes (1).
TYPES OF RETROPERITONEAL TUMORS
Knowing the differential diagnoses of a retroperitoneal tumor will
allow the gynecologist to be aware of the necessary pre-operative
investigations and referrals so as to optimize the management in
the best interest of the patient.
Retroperitoneal tumors are rare growths that originate from
within the retroperitoneal spaces rather than the major retroperi-
toneal organs (2). The classification of retroperitoneal tumors can
be based on type of tissue origin (3). However in this paper,
the retroperitoneal tumors have been divided into solid or cys-
tic tumors as seen in Figure 1. This classification is chosen
because gynecologists usually rely on imaging for the diagno-
sis of retroperitoneal tumors and one of the main radiological
descriptions is whether the tumor is solid or cystic. Most retroperi-
toneal tumors are mesodermal in origin and can arise from any
tissue type present in the retroperitoneum. They can be benign or
malignant (4).
Benign tumors are often incidental findings during inves-
tigations for unrelated symptoms. The most common benign
retroperitoneal tumors are schwannomas, neurofibromas, gan-
glioneuromas, paragangliomas, fibromatosis, and lipomas (5).
Sarcomas make up a third of all the retroperitoneal tumors with
predominantly liposarcomas (70%) and leiomyosarcomas (15%)
(6). Other malignant retroperitoneal tumors include lymphomas,
malignant fibrous histiocytomas (MFH), desmoid tumors, extrag-
onadal germ cell tumors, and metastatic retroperitoneal lym-
phadenopathy (3).
CLINICAL PRESENTATION
Retroperitoneal tumors are commonly misdiagnosed as ovarian
pathologies. It is extremely difficult to differentiate a retroperi-
toneal cyst from an ovarian cyst as the ultrasound findings and
clinical symptoms are very similar.
Symptoms secondary to retroperitoneal tumors are vague and
appear late in the course of the disease caused by compression
of the structures in the retroperitoneum, sometimes causing
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FIGURE 1 |Types of retroperitoneal tumours.
obstruction. Most patients present with abdominal pain and dis-
tension, and will have a palpable mass on clinical examination (7).
Many benign retroperitoneal tumors are diagnosed as an inciden-
tal finding during imaging for unrelated symptoms (8). Patients
can also complain of urinary or gastrointestinal symptoms if there
are pressure effects on these organs from the large tumor.
Gatita and colleagues (9) performed a retrospective analysis
of all the patients treated for primitive retroperitoneal tumors
in their institution between 1999 and 2009. It was interesting to
note that all retroperitoneal tumors diagnosed in their study were
detected in the symptomatic stage. In this study, 83.9% of the 56
patients presented with abdominal pain, 71.4% presented with a
palpable tumor, 51.7% presented with urinary symptoms, 42.9%
presented with gastrointestinal symptoms, and 5.4% presented
with abdominal distension.
DIAGNOSIS
The diagnosis of retroperitoneal tumors is made by radiological
methods and confirmed by histology. In gynecology, ultrasonog-
raphy (US) is usually performed as the first line investigation when
the patient presents to the consultation clinic with abdominal pain
or distension. US is excellent at detecting cystic lesions and is
inexpensive to perform with no radiation involved.
The imaging of choice in diagnosing retroperitoneal tumors is
contrast-enhanced computed tomography (CT). CT plays a vital
role in the localization, characterization, evaluation of the extent
of local invasion, assessment of metastases, and determination of
treatment response of these tumors (3). Although CT imaging
features of most retroperitoneal tumors are non-specific, imaging
analysis of the tumor components, growth pattern, vascularity,
and tumor demographics can lead to a more precise differential
diagnosis (3).
A CT myelography should be performed to rule out Tarlov cyst
(perineurial cyst) pre-operatively for every cystic retroperitoneal
pelvic tumor suspected on initial imaging, as this will alter the
management. It is generally agreed that asymptomatic Tarlov cyst
should be left alone; however, symptomatic ones warrant a referral
to the neurosurgeons for further management (10, 11).
Albeit more costly than CT, magnetic resonance imaging (MRI)
is playing an increasing role in the evaluation of retroperitoneal
soft-tissue masses due to its excellent tissue characterization and
spatial resolution. However, similar to CT, the MRI features of
most retroperitoneal tumors are non-specific, and hence the pre-
diction of a specific histological diagnosis remains a challenge
for radiologists. In general, the dynamic enhancement patterns
in MRI reflect the vascularity of masses, differentiating benign
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from malignant retroperitoneal tumors (12). The tissue-specific
multiplanar capability of high-resolution MRI allows better tumor
localization and internal characterization, thereby serving as a road
map for surgical planning (13).
MANAGEMENT
Complete surgical excision is the treatment of choice for most
retroperitoneal tumors. Malignant retroperitoneal tumors like
the liposarcomas, leiomyosarcomas, or MFH require wide clear
resection margins to allow local control of the disease. The fac-
tors affecting complete margin-negative surgical resection include
tumor biology, invasion of adjacent structures, surgeon experi-
ence, and surgical management in high-volume centers (14–17).
Retroperitoneal sarcomas have poor prognosis with a 5-year local
recurrence-free survival after complete resection ranging between
55 and 78%, and 5-year overall survival between 39 and 68%
(14, 18). Local recurrence is common for retroperitoneal sarco-
mas and is responsible for as high as 75% of sarcoma-related
deaths (18). Surgery should be offered to symptomatic patients
with local recurrence as it provides good palliation and improves
the survival rate for selected patients (19). Palliative debulking
surgery for recurrent retroperitoneal sarcomas of low and inter-
mediate grade can be offered to patients for symptom control and
may improve their quality of life (20).
Benign retroperitoneal tumors such as the schwannomas, neu-
rofibromas, or Tarlov cysts will have to grow to a significant
size before becoming palpable or symptomatic. Management
options for these benign tumors include radiological surveillance
in asymptomatic patients or surgical resection in symptomatic
patients (8, 10, 11).
Chemotherapy is the mainstay treatment for the Ewing fam-
ily of tumors (21). Chemotherapeutic agents such as doxorubicin
and ifosfamide have also been used in the palliation of sympto-
matic advanced retroperitoneal sarcoma (21). There is increas-
ing evidence to support the use of specific chemotherapeutic
agents to target certain histological subtypes. For instance, the
use of gemcitabine and docetaxel for leiomyosarcoma, taxanes for
angiosarcoma, and trabectedin for myxoid/round cell liposarcoma
and leiomyosarcoma (21). If distant metastasis is present, post-
operative adjuvant chemotherapy will also be required to contain
the disease.
Till date, the appropriate role, dose, and timing of radiotherapy
in the management of retroperitoneal sarcoma are still not estab-
lished due to the lack of randomized controlled trials. Retroperi-
toneal sarcomas are often not amenable to conventional radio-
therapy alone (14, 15, 18). Combined modality treatment (combi-
nation of surgery with radiotherapy) has been proven to improve
the local recurrence rate in retroperitoneal sarcomas (22). Sev-
eral observational and retrospective studies have been published
to evaluate the outcomes of pre-, intra-, and post-operative radio-
therapy in the management of retroperitoneal sarcomas (23–26).
Pre-operative radiotherapy offers these advantages: a clear demar-
cated area of tumor for radiotherapy planning, the displacement
of the adjacent radiosensitive structures by the tumor, and the
equivalent therapeutic dose of radiotherapy may be lower in the
pre-operative setting. Post-operative radiotherapy allows the selec-
tion of patients at highest risk of recurrence based on the surgical
margins and histological grade. On the down side, in the post-
operative setting, the adjacent structures will occupy and become
adherent to the tumor bed, increasing the risk of radiation associ-
ated toxicities. Therefore, the use of intra-operative radiotherapy
or intensity-modulated radiation therapy has been investigated in
an attempt to reduce the radiation toxicities (24, 26).
An important development in surgery has been the concept of
concentrating rare surgical conditions and complex operations in
high-volume specialist centers (27). Gutierrez and colleagues (17)
analyzed 4205 patients treated for retroperitoneal tumors in their
study comparing the outcome between low and high-volume cen-
ters. The authors concluded that patients with large, high-grade,
especially retroperitoneal tumors should be treated exclusively in
high-volume centers to ensure improved short-term surgical out-
comes, lower local recurrence rate, and superior overall survival
rate (17). Therefore, the management of retroperitoneal tumors
should be limited to a few dedicated, experienced multidiscipli-
nary centers with the necessary expertise, not just to optimize
patient care, but also to benefit training and research. Being a rare
and complex tumor, retroperitoneal sarcomas should be managed
by an experienced multidisciplinary team in a specialized sarcoma
center (28).
Research into the tumor biology of retroperitoneal sarcomas
shows promise of the development of novel biological therapies to
target the various molecular pathways (29). This avenue of treat-
ment will broaden the management options in future, especially
for patients not fit for surgery.
DIAGNOSTIC AND THERAPEUTIC CHALLENGE
In addition to the inaccessibility of the retroperitoneal region,
retroperitoneal tumors often show no or non-specific symptoms
until they have grown to a substantial size. As a result, they are
usually very large at presentation. In other words, the clinical man-
ifestations of retroperitoneal tumors are variable and only reveal
themselves after a long latency period when the tumors are large
enough to cause compression, displacement, or invasion of adja-
cent structures. This late diagnosis is not optimal as the prognosis
of a malignant retroperitoneal tumor is influenced by the time of
diagnosis.
The diagnosis is also not straightforward as there are many
visceral and vascular structures located in the pelvis and retroperi-
toneal space. Often on US, a retroperitoneal tumor is mistaken for
a gynecological pelvic tumor, only to be proven wrong during
surgery. Therefore, CT and MR imaging play a vital role in the
diagnosis of a retroperitoneal tumor. However, it is still a diag-
nostic challenge as many of the imaging features are non-specific
for a particular tumor. Hence, a definitive diagnosis can only be
established at histopathological examination.
In addition to the above mentioned diagnostic dilemmas,
retroperitoneal sarcomas pose several therapeutic challenges.
These tumors have variable radiosensitivity, and are often adja-
cent to radiosensitive structures with low radiation tolerance in
the retroperitoneum.
Being in an anatomically complex and surgically inaccessible
site with surrounding vital structures, it may not always be pos-
sible to obtain a complete resection of the retroperitoneal tumor
with sufficient clear margins, especially when most tumors are
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large at presentation, hence compounding the technical difficulty
of the surgery. Inexperienced surgeons may find it challenging to
operate on a tumor in the complex retroperitoneum. It is essen-
tial for surgeons to have sound knowledge of the anatomy of the
retroperitoneal space in order to avoid injury to the adjacent vis-
ceral, vascular, and nervous structures, resulting in complications
like hemorrhage and neurological deficits.
CONCLUSION
There is a wide spectrum of rare tumors in the retroperitoneum,
both benign and malignant. The presentation of these tumors
is usually late; patients commonly present with symptoms of
abdominal pain or a palpable tumor. CT and MR imaging play an
important role in the diagnosis of retroperitoneal tumors. How-
ever, as the imaging features are non-specific, the diagnosis can
only be confirmed by histology. Complete surgical resection is
the mainstay treatment when a patient is symptomatic. A benign
retroperitoneal tumor can be treated conservatively with frequent
radiological surveillance if the patient is asymptomatic. In the case
of retroperitoneal sarcomas, this is best managed in a dedicated,
experienced multidisciplinary sarcoma center. It is beneficial to
gynecologists to be aware of the management of retroperitoneal
tumors and its pitfalls.
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